What this covers: The interplay between the major endocrine axes (HPG, HPA, and GH), including testosterone, estrogen balance, and GH-axis support.
Test first: Establish a baseline including total and free testosterone, SHBG, LH and FSH, estradiol, IGF-1, and AM cortisol.
Research focus: GH secretagogues, reproductive peptides (Kisspeptin-10), and Tesamorelin.
Key thing to know: Symptoms alone are not diagnostic, so a full hormone panel is the starting point; interpret with a licensed provider.
What does this goal involve?
Hormonal balance research in a peptide context spans several connected areas.
The endocrine axes: Hormonal-balance research examines how the major endocrine axes interact:
- HPG axis (hypothalamic-pituitary-gonadal) — sex hormone production.
- HPA axis (hypothalamic-pituitary-adrenal) — stress response.
- GH axis (growth hormone) — body composition and repair.
These are deeply interconnected — dysfunction in one affects the others (for example, chronic cortisol can suppress LH pulsatility and testosterone; GH decline lowers IGF-1). Research focuses on identifying the primary driver before choosing an approach.
Symptoms are not diagnostic: A key principle: symptoms are not diagnostic. Fatigue, poor recovery, low libido, mood changes, and body-composition decline can each stem from testosterone deficiency, GH deficiency, thyroid dysfunction, cortisol dysregulation, or insulin resistance. A comprehensive lab panel is the only way to tell which system is driving symptoms.
The evidence base: The evidence base here is unusually strong for a peptide category, since GH secretagogues have been prescribed clinically for decades. Sermorelin and Tesamorelin have the most developed clinical profiles; Ipamorelin and CJC-1295 are well characterized as a combination. PT-141 adds the sexual-health dimension via central melanocortin activation.
Biomarkers to establish before exploring this goal.
Research protocols for this goal area typically reference the following biomarkers as baseline context. Testing these first gives you and your healthcare provider the most relevant starting information.
Primary sex hormone baseline,total testosterone alone is an incomplete picture without the free fraction, which reflects the bioavailable portion that actually enters cells. Both values are required to correctly characterize testosterone status before any hormonal research protocol.
Without SHBG, total testosterone is an incomplete picture,high SHBG binds testosterone and reduces its bioavailability despite normal total levels. Distinguishing high-SHBG low-free-T from true testosterone deficiency determines which research approach is mechanistically appropriate.
Distinguish primary (testicular/ovarian) from secondary (pituitary/hypothalamic) hormonal dysfunction,the distinction is clinically critical because research approaches for each are entirely different, and HPG axis stimulation research (Kisspeptin-10) is only relevant in secondary dysfunction.
Balance marker for all hormonal protocols in both men and women,both excess and deficiency impair wellbeing and function, and GH secretagogue protocols can affect aromatase activity, making estradiol monitoring essential throughout any GH-axis research.
GH axis baseline and the primary monitoring metric for GH secretagogue research,GH and sex hormones have direct interactions through IGF-1-mediated anabolism, and this baseline establishes the starting point for assessing GH protocol response throughout research.
HPA axis baseline,cortisol excess directly suppresses LH pulsatility, testosterone production, and GH secretion through hypothalamic mechanisms. Identifying cortisol dysregulation before hormonal research avoids the common error of treating downstream testosterone deficiency without addressing its upstream cortisol driver.
Thyroid dysfunction can closely resemble hormonal deficiency — fatigue, body-composition changes, libido changes, mood disruption — and is worth reviewing before attributing symptoms to the HPG or GH axis. It is a common confounder in hormonal research.
What does the research focus on for this goal?
Research for this goal concentrates on a few distinct compounds and pathways.
GH secretagogues: The most evidence-supported approach in this category. Sermorelin and Ipamorelin have documented effects on GH and IGF-1 in aging adults, with downstream changes in body composition, energy, and recovery. GH and testosterone support each other, so this research is especially relevant when both decline together (common over 40).
Kisspeptin-10: A more targeted approach to HPG-axis stimulation. Kisspeptin stimulates GnRH release from the hypothalamus, driving LH and FSH and, in turn, testosterone and estradiol — working through natural HPG activation rather than exogenous hormones. Human research documents LH-pulsatility stimulation after Kisspeptin-10; most relevant when LH and FSH are low-normal.
Tesamorelin: Tesamorelin's FDA approval for lipodystrophy (a body-composition condition driven by visceral fat) is the most clinically rigorous evidence for GH-axis peptide effects on body composition. Approval required controlled human trials, giving it a distinct evidence tier versus non-approved GH secretagogues. Its relevance here is through body-composition effects mirroring combined testosterone and GH changes.
Peptides commonly researched for this goal.
The peptides below appear in research literature in connection with this goal. This is not a recommendation to use any of these compounds. Always consult a licensed healthcare provider.
GHRH analog with the longest clinical prescribing history among GH secretagogues,documented effects on GH and IGF-1 restoration in age-related GH deficiency make it the reference compound for GH-axis hormonal research with the most developed human safety profile.
FDA-approved GHRH analog with RCT evidence for body composition improvement and visceral fat reduction,the regulatory approval for lipodystrophy provides the strongest clinical evidence for GH-axis peptide effects on the body composition dimension of hormonal balance.
Selective GHRP studied for GH release with minimal cortisol or prolactin elevation,the cortisol-sparing property is particularly valuable in hormonal balance research where cortisol suppression of the HPG axis is a primary concern alongside GH axis optimization.
Long-acting GHRH analog commonly researched in combination with Ipamorelin for synergistic GH pulse amplification,the sustained IGF-1 elevation documented in clinical studies supports continuous anabolic signaling relevant to the body composition dimension of hormonal optimization.
FDA-approved melanocortin agonist (Vyleesi) for HSDD in premenopausal women,addresses the sexual health and desire dimension of hormonal balance through central hypothalamic activation, independent of vascular mechanisms and complementary to hormonal optimization protocols.
What research protocols typically examine.
Timeline
Hormonal research protocols require a minimum of 3–6 months for meaningful changes in sex hormone levels and body composition markers. GH secretagogue protocols require IGF-1 monitoring at 8-week intervals. Symptom changes may be noted earlier but marker normalization takes longer.
Monitoring
Full panel at baseline and 8 weeks minimum: testosterone (total and free), IGF-1, estradiol, SHBG, LH, FSH, AM cortisol, TSH. Body composition assessment via DEXA at baseline and 3–6 month intervals for GH secretagogue protocols.
Limitations
Hormonal balance is among the most individual of any research area — population reference ranges reflect averages, not individual baselines. Symptom resolution alongside marker normalization is the relevant research endpoint; marker changes without symptom improvement do not constitute research success.